Loading Events

« All Events

  • This event has passed.

SMi 3rd Annual Conference – Superbugs & Superdrugs USA

November 12, 2018 - November 13, 2018

Antimicrobial resistance, leading to the development of superbugs, is a major threat to public health and continues to increase as a problem, due to continued misuse of antibiotics. With pharmaceutical companies showing less focus on the development of new antibiotics, several incentive initiatives have been set up – CARBX, BARDA, IMI (EU) – in order to encourage reinvestments. From a governmental point of view, the challenge lies in encouraging companies to develop new antimicrobial drugs and to strengthen and maintain the pipeline of antibiotics and other antimicrobials currently being developed.

To address the ever-growing need of informative and thought-provoking discussions,Superbugs &Superdrugs USA conference will offer a jam-packed agenda with presentations from key industry leaders and up-and-coming thinkers, within the field.

This years’ Superbugs &Superdrugs USA conference programme will help participants to learn about pathogen focused drug development; discover the best methods to overcome bacterial resistance through novel modes of action; discuss the state of developments within the antifungal space; develop an understanding of funding opportunities which support antibacterial research and development; gain insight into new techniques through case-study examples of rapid diagnostic methods currently being used within the field, making this event the perfect platform to strengthen knowledge in key principles.

Speakers include:

  • Anthony Simon Lynch, Senior Scientific Director, Janssen
  • William Weiss, Director, Pre-Clinical Services, UNT Health Science Center
  • Tina Guina, Program Officer, Drug Development Section, NIAID/NIH
  • Mark Albrecht, Project Officer, HHS/ASPR/BARDA
  • Antonio DiGiandomenico, Principal Scientist, MedImmune
  • Andrew Tomaras, VP & Director of Microbiology, Bacterioscan
  • Dan Pevear, Sr Vice President & Director of Microbiology, VenatoRx
  • Ian Friedland, Clinical Consultant, ex-CMO, Achaogen

Plus, topical workshops on November 14:

  • Rapid diagnostics for drug resistance: Are we there yet?
  • Avoiding the post antibiotic era: the challenges and solutions to successful commercialisation of new antibiotics

Further details at http://www.superbugs-usa.com/phhqWL

Twitter – @SMIpharm&#smibugs
LinkedIn – SMi Pharma


+44 (0)20 7827 6000


November 12, 2018
November 13, 2018


+44 (0)20 7827 6000


New Jersey, USA

To ensure you get the best experience on our website, we use cookies to analyze traffic and for ads measurements purposes including for serving Industry-based ads. By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.